BETHESDA, Md., Aug. 8, 2019 /PRNewswire/ -- The American College of Medical Genetics and Genomics (ACMG) is announcing the establishment of an Evidence-Based Guidelines (EBG) Program, including a staff team dedicated to new evidence-based guideline development in the medical genetics and genomics field.

- Sierra preparing to launch the MOMENTUM Phase 3 myelofibrosis clinical trial expected in Q4 2019 -- Exploring non-dilutive options to support future continued development of DDR portfolio - VANCOUVER, Aug 8, 2019 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on advancing targeted therapeutics

BURLINGTON, ON and BRANTFORD, ON, Aug. 8, 2019 /PRNewswire/ - Rapid Dose Therapeutics Corp. (CSE: DOSE), ("RDT")

VANCOUVER, Aug. 8, 2019 /PRNewswire/ - Choom™ (CSE: CHOO; OTCQB: CHOOF), is pleased to announce that an Alberta provincially approved cannabis retail licensee ("Licensee") is opening a cannabis retail store in Medicine Hat, Alberta operating under the Choom brand.

OLDWICK, N.J., Aug. 8, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it has dosed the first patients in its PREVAIL (PRV-3279 EVAluation In Lupus) study, a Phase 1b/2a clinical trial evaluating PR

BERLIN and CAMBRIDGE, Mass., Aug. 8, 2019 /PRNewswire/ -- Bayer AG and BlueRock Therapeutics today announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology and immunology, using a proprietary in

SOUTH SAN FRANCISCO, Calif., Aug. 8, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced that its Chief Business Officer, Stephe

SALT LAKE CITY, Aug. 8, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today reported financial results for the second calendar quarter of 2019.  PolarityTE will host a conference call and webcast today, August 8, 2019 a

DUBLIN, Ohio, Aug. 8, 2019 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported fourth quarter fiscal year 2019 revenues of $37.4 billion, an increase of 6 percent from the fourth quarter last year. GAAP operating earnings were $307 million and non-GAAP operating earnings were $507 m

INDIANAPOLIS, Aug. 8, 2019 /PRNewswire/ -- Initial results from a feasibility study conducted by Eli Lilly and Company (NYSE: LLY), Evidation Health, and Apple Inc. (NASDAQ: AAPL) showed that an iPhone, Apple Watch, iPad and the Beddit sleep monitoring device, in combination with digital apps may be able to differentiate people with mild cognitive impairment (MCI) a